UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 207

Sortiert nach

Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning

Gastroenterology (New York, N.Y. 1943), 2020-10, Vol.159 (4), p.1406-1416.e11

2020

Volltextzugriff (PDF)

Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies

Clinical cancer research, 2014-10, Vol.20 (20), p.5322-5330

2014

Volltextzugriff (PDF)

KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

Journal of clinical oncology, 2009-12, Vol.27 (35), p.5931-5937

2009

Volltextzugriff (PDF)

A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment

Molecular oncology, 2020-10, Vol.14 (10), p.2384-2402

2020

Volltextzugriff (PDF)

Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial

Journal of clinical oncology, 2008-06, Vol.26 (16), p.2690-2698

2008

Volltextzugriff (PDF)

Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial

Journal of clinical oncology, 2009-11, Vol.27 (33), p.5519-5528

2009

Volltextzugriff (PDF)

Results of the UK NEQAS for Molecular Genetics reference sample analysis

Journal of clinical pathology, 2018-11, Vol.71 (11), p.989

2018

Volltextzugriff (PDF)

Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNA

Scientific reports, 2021-02, Vol.11 (1), p.3138-3138, Article 3138

2021

Volltextzugriff (PDF)

Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy

NPJ precision oncology, 2024-04, Vol.8 (1), p.89-89, Article 89

2024

Volltextzugriff (PDF)

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials

The Journal of pathology, 2016-03, Vol.238 (4), p.562-570

2016

Volltextzugriff (PDF)

Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing

Analytical cellular pathology (Amsterdam), 2011-01, Vol.34 (1-2), p.61-66

2011

Volltextzugriff (PDF)

Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia

British journal of cancer, 2020-10, Vol.123 (8), p.1280-1288

2020

Volltextzugriff (PDF)

Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring

Journal of clinical oncology, 2021-11, Vol.39 (33), p.3705-3715

2021

Volltextzugriff (PDF)

FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing

Journal of clinical pathology, 2023-08, Vol.76 (8), p.548

2023

Volltextzugriff (PDF)

Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies

The Journal of pathology, 2018-05, Vol.245 (1), p.19-28

2018

Volltextzugriff (PDF)

RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009–2016)

Virchows Archiv : an international journal of pathology, 2017-12, Vol.471 (6), p.721-729

2017

Volltextzugriff (PDF)

EGFR Amplification in Metastatic Colorectal Cancer

JNCI : Journal of the National Cancer Institute, 2021-11, Vol.113 (11), p.1561-1569

2021

Volltextzugriff (PDF)

Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone

British journal of cancer, 2021-10, Vol.125 (8), p.1080-1088

2021

Volltextzugriff (PDF)

How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation

Journal of clinical pathology, 2017-01, Vol.70 (1), p.58

2017

Volltextzugriff (PDF)

Prediction of the response of colorectal cancer to systemic therapy

The lancet oncology, 2002-02, Vol.3 (2), p.75-82

2002

Volltextzugriff (PDF)

Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer

Clinical cancer research, 2023-10, Vol.29 (20), p.4153

2023

Volltextzugriff (PDF)

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

Journal of clinical oncology, 2021-11, Vol.39 (33), p.3693-3704

2021

Volltextzugriff (PDF)

Artificial Intelligence-Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in RAS Wild-Type Metastatic Colorectal Cancer

Clinical cancer research, 2021-06, Vol.27 (12), p.3422-3431

2021

Volltextzugriff (PDF)

1 – 25 von 207

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(194)
Mit Volltextzugriff
(183)

Publikationsform

Sprache

Englisch
(207)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning

Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies

KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment

Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial

Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial

Results of the UK NEQAS for Molecular Genetics reference sample analysis

Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNA

Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy

Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials

Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing

Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia

Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring

FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing

Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies

RAS screening in colorectal cancer: a comprehensive analysis of the results from the UK NEQAS colorectal cancer external quality assurance schemes (2009–2016)

EGFR Amplification in Metastatic Colorectal Cancer

Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone

How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation

Prediction of the response of colorectal cancer to systemic therapy

Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

Artificial Intelligence-Assisted Amphiregulin and Epiregulin IHC Predicts Panitumumab Benefit in RAS Wild-Type Metastatic Colorectal Cancer

Suchergebnisse filtern